Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study

NCT00775463 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT00775463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00775463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study
Lead sponsor
United Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
July 31, 2011
Enrollment
148 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

scleroderma, systemic sclerosis